In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Commentary|Videos|August 4, 2025
Voices in Lymphoma: Women Shaping the Future of Care
Author(s)Clémentine Sarkozy, MD, PhD, Carla Casulo, MD
Clémentine Sarkozy, MD, PhD, and Carla Casulo, MD, detail the evolution of lymphoma management strategies.
Advertisement
Clémentine Sarkozy, MD, PhD, and Carla Casulo, MD, detail the evolution of lymphoma management strategies. Sarkozy is a member of the Service d'hématologie at Institut Curie in Saint Cloud, France. Casulo is an associate professor of medicine and assistant director of Cancer Research Training and Education at the Wilmot Cancer Institute in Rochester, New York.
Advertisement
Related to this article
A rituximab biosimilar has been approved by the FDA.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5